Xvivo Perfusion Ab Stock Cash And Equivalents
| XVIVO Stock | SEK 381.00 11.50 2.93% |
Xvivo Perfusion AB fundamentals help investors to digest information that contributes to Xvivo Perfusion's financial success or failures. It also enables traders to predict the movement of Xvivo Stock. The fundamental analysis module provides a way to measure Xvivo Perfusion's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Xvivo Perfusion stock.
Xvivo |
Xvivo Perfusion AB Company Cash And Equivalents Analysis
Xvivo Perfusion's Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes.
Current Xvivo Perfusion Cash And Equivalents | 398.7 M |
Most of Xvivo Perfusion's fundamental indicators, such as Cash And Equivalents, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Xvivo Perfusion AB is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Cash equivalents represent current assets that are easily convertible to cash such as short term bonds, savings account, money market funds, or certificate of deposits (CDs). One of the important consideration companies make when classifying assets as cash equivalent is that investments they report on their balance sheets under current assets should have almost no risk of change in value over the next few months (usually three months).
| Competition |
In accordance with the recently published financial statements, Xvivo Perfusion AB has 398.7 M in Cash And Equivalents. This is 51.43% lower than that of the Health Care Equipment & Supplies sector and 28.54% lower than that of the Health Care industry. The cash and equivalents for all Sweden stocks is 85.25% higher than that of the company.
Xvivo Cash And Equivalents Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Xvivo Perfusion's direct or indirect competition against its Cash And Equivalents to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Xvivo Perfusion could also be used in its relative valuation, which is a method of valuing Xvivo Perfusion by comparing valuation metrics of similar companies.Xvivo Perfusion is currently under evaluation in cash and equivalents category among its peers.
Xvivo Fundamentals
| Return On Equity | 0.0136 | |||
| Return On Asset | 0.0057 | |||
| Profit Margin | 0.04 % | |||
| Operating Margin | 0.04 % | |||
| Current Valuation | 5.54 B | |||
| Shares Outstanding | 29.83 M | |||
| Shares Owned By Insiders | 12.25 % | |||
| Shares Owned By Institutions | 54.00 % | |||
| Price To Earning | 662.55 X | |||
| Price To Book | 4.23 X | |||
| Price To Sales | 16.58 X | |||
| Revenue | 258.39 M | |||
| Gross Profit | 296.96 M | |||
| EBITDA | 39.2 M | |||
| Net Income | 8.15 M | |||
| Cash And Equivalents | 398.7 M | |||
| Cash Per Share | 7.45 X | |||
| Total Debt | 1.52 M | |||
| Debt To Equity | 1.20 % | |||
| Current Ratio | 4.69 X | |||
| Book Value Per Share | 47.94 X | |||
| Cash Flow From Operations | (12.06 M) | |||
| Earnings Per Share | 0.99 X | |||
| Target Price | 383.33 | |||
| Number Of Employees | 133 | |||
| Beta | 1.97 | |||
| Market Capitalization | 7.48 B | |||
| Total Asset | 1.54 B | |||
| Retained Earnings | 22 M | |||
| Working Capital | 81 M | |||
| Current Asset | 98 M | |||
| Current Liabilities | 17 M | |||
| Net Asset | 1.54 B |
About Xvivo Perfusion Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Xvivo Perfusion AB's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Xvivo Perfusion using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Xvivo Perfusion AB based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Xvivo Stock Analysis
When running Xvivo Perfusion's price analysis, check to measure Xvivo Perfusion's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Xvivo Perfusion is operating at the current time. Most of Xvivo Perfusion's value examination focuses on studying past and present price action to predict the probability of Xvivo Perfusion's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Xvivo Perfusion's price. Additionally, you may evaluate how the addition of Xvivo Perfusion to your portfolios can decrease your overall portfolio volatility.